Edition:
United States

Therapix Biosciences Ltd (TRPX.OQ)

TRPX.OQ on NASDAQ Stock Exchange Capital Market

5.66USD
3:59pm EST
Change (% chg)

$0.26 (+4.81%)
Prev Close
$5.40
Open
$5.36
Day's High
$5.71
Day's Low
$5.22
Volume
7,796
Avg. Vol
5,446
52-wk High
$10.90
52-wk Low
$4.42

Chart for

About

Therapix Biosciences Ltd, formerly Nasvax Ltd, is an Israel-based company active in the pharmaceutical sector. The Company develops improved vaccines and immunotherapeutics. Its products include Anti-CD3 oral immunotherapy, directed toward the treatment of inflammatory and autoimmune diseases; Group-common Pneumococcal Vaccine,... (more)
No analyst recommendations are available for .

Overall

Beta: -2.50
Market Cap(Mil.): ₪61.99
Shares Outstanding(Mil.): 138.36
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.13 15.67
EPS (TTM): -- -- --
ROI: -- 15.10 34.62
ROE: -- 16.59 16.00

Therapix expects to have results of Tourette's drug trial by end of first quarter

TEL AVIV Israel's Therapix Biosciences said on Monday it expects by the end of March to have the results from its mid-stage trial of a cannabinoid-based drug for treating Tourette's syndrome which could be worth billions of dollars in revenues.

Dec 04 2017

Therapix expects to have results of Tourette's drug trial by end of Q1

TEL AVIV, Dec 4 Israel's Therapix Biosciences said on Monday it expects by the end of March to have the results from its mid-stage trial of a cannabinoid-based drug for treating Tourette's syndrome which could be worth billions of dollars in revenues.

Dec 04 2017

BRIEF-Therapix Biosciences plans preclinical study to evaluate opioid-sparing effects of two innovative synthetic cannabinoids

* Therapix Biosciences Ltd plans preclinical study to evaluate opioid-sparing effects of two innovative synthetic cannabinoids Source text for Eikon: Further company coverage:

Nov 10 2017

BRIEF-Therapix Biosciences Q3 loss per share $0.30

* Therapix Biosciences reports third quarter 2017 financial results and provides business update

Nov 09 2017

BRIEF-Therapix Biosciences' board chairman, Ascher Shmulewitz, appointed as interim chief executive officer

* Therapix Biosciences' board chairman, Ascher Shmulewitz, appointed as interim chief executive officer Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Nov 02 2017

BRIEF-Therapix initiates non-clinical studies for its antibacterial program

* Therapix- Initiated non-clinical studies to evaluate efficacy of compound THX-150 with Weizmann Institute of Science & Tel Aviv Sourasky Medical Center​

Oct 30 2017

BRIEF-Therapix Biosciences and Assuta Medical Center to initiate clinical trial in obstructive sleep apnea

* Therapix Biosciences and Assuta Medical Center to initiate clinical trial in obstructive sleep apnea Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Oct 18 2017

BRIEF-THERAPIX SIGNS FORMULATION DEVELOPMENT, CLINICAL MANUFACTURING AGREEMENT WITH CATALENT FOR THX-TS01

* THERAPIX SIGNS FORMULATION DEVELOPMENT AND CLINICAL MANUFACTURING AGREEMENT WITH CATALENT FOR THX-TS01

Oct 06 2017

BRIEF-Therapix's therapy shows reversal of age-related cognitive impairment in pre-clinical study

* Therapix's first-in-class therapy demonstrates reversal of age-related cognitive impairment in pre-clinical study Source text for Eikon: Further company coverage:

Sep 27 2017

BRIEF-Therapix Biosciences posts Q2 loss per share $0.54

* Therapix Biosciences reports second quarter 2017 financial results and provides business update

Aug 10 2017

Earnings vs. Estimates